Articles

Videos

Podcasts

Clinical Role

Analysis results expand understanding of the impact of the company’s medicines in early stages with the goal or providing patients with durable and robust outcomes from their first treatment.

Genentech Releases Positive Data from Broad Blood Cancer Portfolio

Breast cancer screening guidelines using mammography vary among guiding bodies, including the American Cancer Society and the American Academy of Family Physicians.

The Impact of COVID-19 on Cervical, Breast Cancer Screenings

Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.

Oncology Overview: Abemaciclib, a CDK4/6 Inhibitor for Prostate Cancer

Combination therapy with both nivolumab and relatlimab leads to increased T-cell activation compared with monotherapy with either agent alone.

Opdualag From Bristol Myers Squibb

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.

HOPA Expert: To Mitigate the ‘Great Migration of Hematology/Oncology Pharmacists,’ First We Need to Understand Why

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented. 

Pandemic Created Combat Like Trauma for Pharmacists 

Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Daily Medication Pearl: Capecitabine (Xeloda)

Treatment identifies patients with ROS1 fusion-positive non-small cell lung cancer or those with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek may be appropriate.

FDA Approves FoundationOne CDx for Use With Entrectinib For NSCLC, Solid Tumors

In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.

FDA Approves Dabrafenib Plus Trametinib for Unresectable, Metastatic Solid Tumors With BRAF V600E Mutation

PAPs can significantly reduce OOP costs for patients.

Assessing the Impact of Patient Assistance Programs on Financial Toxicity in Oral Oncology

® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.

Specialty Pharmacy